Diabetes development firm Dia-B Tech Ltd intends to move to Phase II trials of its drug ISF402 for the treatment of type 2 diabetes, after receiving “encouraging” results for the Phase I trial.
Diabetes development firm Dia-B Tech Ltd intends to move to Phase II trials of its drug ISF402 for the treatment of type 2 diabetes, after receiving “encouraging” results for the Phase I trial.